@ajnelson Profile picture

Adam Nelson

@ajnelson

Cardiologist | Clinical Trialist | HSR. Passionate about prevention, value, learning health systems; keen runner; father of boys. RAH | UofA | VHI | DCRI

Similar User
Steve Nicholls photo

@ProfSNicholls

Chris Wong photo

@WongChrisX

Clara Chow photo

@clara_chow

CSANZ photo

@thecsanz

Bradley Pitman photo

@pitmabm

Monash Victorian Heart Institute photo

@MonashVHI

Adrian “WE NEED RCTS!” Hernandez photo

@texhern

Jennifer Rymer photo

@jennifer_rymer

Michael Nanna photo

@MichaelGNanna

Alex Fanaroff photo

@ACFanaroff

Eric D. Peterson photo

@ericpetersonMD

Dr Kristen Bubb photo

@kristenbubb

Dr John Younger photo

@Dr_JYounger

Daniel Scherer photo

@iamdanscherer

Kunal Jha photo

@kunaljhamd

Looking forward to it @drhungo !!!

#ESCCongress2024 done 👏🏻 👏🏻 Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague @ajnelson Conference link/discount below 👇🏼 Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane invt.io/1txbv5ph0ub



Adam Nelson Reposted

#ESCCongress2024 done 👏🏻 👏🏻 Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague @ajnelson Conference link/discount below 👇🏼 Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane invt.io/1txbv5ph0ub


Adam Nelson Reposted

Results of the CAMERA-MRI II study LBCT #ESC2024: catheter ablation in AF and LVSD with LV fibrosis superior to medical therapy with respect to LVEF improvement, functional status, patient symptoms and reverse LA remodeling @ESCardioNews @drjohnm @peterkistler3 @drsunnyprabhu

Tweet Image 1

Adam Nelson Reposted

Excited to launch @TheLancet Commission on Finding Solutions for the Cardiovascular Disease Burden in the Asia Pacific Region with my good friend @lamcardio - a lot of work lies ahead with energetic colleagues @richardhorton1 @dukenus @MonashVHI

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Adam Nelson Reposted

Thrilled to present the results from the WITHDRAW-AF randomized clinical trial at #ESC2024 - low LVSD relapse rates in recovered AFCM following withdrawal of HF pharmacotherapy @BakerResearchAu @UniMelb @AlfHeartCentre @escardio @drjohnm

Tweet Image 1

Adam Nelson Reposted

Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression Highlighting epidemiological & therapeutic synergies between CKD & CV disease Cardio-kidney-metabolic #simpub for #ESCCongress in @JACCJournals

New analysis from CANVAS and CREDENCE trials reveals a bidirectional relationship between CV events and #CKD progression in type 2 #diabetes bit.ly/3X747wK #ESCCongress #JACC #T2D #MACE @brendonneuen @mvaduganathan

Tweet Image 1
Tweet Image 2


Adam Nelson Reposted

Patients with HFrEF have ⬆️ incident cancer but undergo ⬇️ cancer screening than the general population (despite expressing interest). Should we include cancer screening in HFrEF programs? japscjournal.com/articles/cance… #cardiooncology #reversecardiooncology @MonashVHI

Tweet Image 1

Fantastic work by @cardiopharmnerd - discharge pathways post PCI and CABG look different but use of secondary prevention medications should be similar… plenty of opportunities to improve adoption of evidence based therapies. doi.org/10.1016/j.hlc.…

Absolutely stoked to be featured in the Limbic yesterday, check out the story behind revascularization and secondary prevention medication use on Victoria: Preventive meds after MI depend on revascularisation strategy: thelimbic.com/cardiology/pre…



Thanks for the opportunity @ProfSNicholls & @lamcardio ... Despite housing 60% of the global burden of CVD, our earlier work has shown that < 10% of participants enrolled in seminal cardiometabolic studies are from APAC. Huge opportunities @the_apcmc jacc.org/doi/abs/10.101…

Tweet Image 1

Time to harness the incredible potential of clinicians, researchers, health services and governments across the Asia Pacific region to tackle this high burden disease @JAMA_current @lamcardio @ajnelson @MonashVHI



Adam Nelson Reposted

REGISTER: thelimbic.com/nephrology/car… A MDT panel presents the latest updates on the use of disease-modifying treatments in cardio-renal metabolic disease and discusses models of care for improved patient outcomes. @brendonneuen @KrishRathika @ajnelson @DrSarahGlastras @ANZSN

Tweet Image 1

Adam Nelson Reposted

Many practical challenges affect ASCVD prevention in patients with cancer treated immunotherapy. Huge scope for opportunistic screening and implementation research in #CardioOncology @ProfSNicholls @profevasegelov @ajnelson @MonashVHI @ESC_Journals doi.org/10.1093/eurjpc…

Tweet Image 1

Great to have @SJGreene_md all the way from @DCRINews here in Adelaide @thecsanz reminding us of the importance of simultaneous commencement & rapid titration of HFrEF therapies. Incredible body of work highlighting gaps and importantly a path forward! @lamcardio

Tweet Image 1
Tweet Image 2

Great to have @WongChrisX back in town kicking off @SAHMRI_Heart emerging leaders symposium. Translational data linking dietary factors with propensity for arrhythmia. @UniofAdelaide @Elliott_AD @PrashSanders @ChrisBursill

Tweet Image 1

Adam Nelson Reposted

Excellent summary of the renal benefits SGLT2 inhibitors by ⁦@SantosGallegoMD⁩ at #ADA2023@JavedButler1⁩ ⁦@hvanspall⁩ ⁦@ajnelson⁩ ⁦@MWilkinsonMD⁩ ⁦@MountSinaiHeart

Tweet Image 1

Adam Nelson Reposted

Patients receiving immune checkpoint inhibitors for cancer routinely have their BP checked when they attend for treatment. Could we be repurposing this for hypertension screening? nature.com/articles/s4137… @ProfSNicholls @ajnelson @profevasegelov @MonashVHI #CardioOncology


Loading...

Something went wrong.


Something went wrong.